BioNTech SE (BNTX)
NASDAQ: BNTX · Real-Time Price · USD
98.66
-5.10 (-4.92%)
At close: Sep 8, 2026, 4:00 PM EDT
98.38
-5.38 (-5.19%)
Pre-market: Sep 9, 2026, 6:47 AM EDT
BioNTech SE Employees
BioNTech SE had 7,807 employees as of December 31, 2025. The number of employees increased by 1,035 or 15.28% compared to the previous year.
Employees
7,807
Change (1Y)
1,035
Growth (1Y)
15.28%
Revenue / Employee
$387,797
Profits / Employee
-$246,785
Market Cap
24.78B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7,807 | 1,035 | 15.28% |
| Dec 31, 2024 | 6,772 | 639 | 10.42% |
| Dec 31, 2023 | 6,133 | 1,603 | 35.39% |
| Dec 31, 2022 | 4,530 | 1,448 | 46.98% |
| Dec 31, 2021 | 3,082 | 1,141 | 58.78% |
| Dec 31, 2020 | 1,941 | 631 | 48.17% |
| Dec 31, 2019 | 1,310 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines AG | 12,000 |
| Genmab | 3,119 |
| Jazz Pharmaceuticals | 2,890 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| Insmed | 1,664 |
| Ascendis Pharma | 1,189 |
| BridgeBio Pharma | 1,003 |
BNTX News
- 1 day ago - BioNTech downgraded to Market Perform from Outperform at BMO Capital - TheFly
- 9 days ago - BioNTech price target lowered to $136 from $142 at Canaccord - TheFly
- 11 days ago - BioNTech Stock (BNTX) Is Tumbling on Friday – Here’s Why - TipRanks
- 11 days ago - Cevumeran trial termination a ‘clear setback’ for BioNTech, says BMO Capital - TheFly
- 11 days ago - mRNA immunotherapy discontinuation a negative for BioNTech, says Morgan Stanley - TheFly
- 11 days ago - BioNTech to terminate mid-stage trial of mRNA cancer vaccine - Reuters
- 11 days ago - BioNTech drops 9% after ending Phase 2 colorectal cancer trial - TheFly
- 11 days ago - BioNTech to terminate Phase 2 monotherapy trial of cevumeran - TheFly